Vicarious Surgical

Yahoo Finance • last month

Vicarious Surgical targets design freeze by end of 2026 through burn reduction and outsourcing initiatives

Earnings Call Insights: Vicarious Surgical Inc. (RBOT) Q3 2025 MANAGEMENT VIEW * CEO Stephen From emphasized a transition from assessment to execution, with a clear focus on reaching design freeze for the production-equivalent system b... Full story

Yahoo Finance • 3 months ago

Vicarious Surgical raises $5.9M in direct and private placement offering; shares down

* Vicarious Surgical (NYSE:RBOT [https://seekingalpha.com/symbol/RBOT]) entered into a securities purchase agreement with a single institutional investor to raise $5.9M through a registered direct offering and concurrent private placemen... Full story

Yahoo Finance • 4 months ago

Vicarious Surgical Inc. (NYSE:RBOT) Reports Narrower Q2 2025 Loss Amid Cost Optimization Efforts

Vicarious Surgical Inc. (NYSE:RBOT [https://www.chartmill.com/stock/quote/RBOT/profile]) reported its second-quarter 2025 financial results, revealing a net loss per share of $2.23, which was narrower than the analyst consensus estimate of... Full story

Yahoo Finance • 5 months ago

Vicarious Surgical appoints Stephen From as new CEO

WALTHAM, Mass. - Surgical robotics company Vicarious Surgical Inc. (NYSE:RBOT), currently valued at $7.9 million in market capitalization, announced Thursday the appointment of Stephen From as Chief Executive Officer and board member, effe... Full story

Yahoo Finance • 6 months ago

Vicarious Surgical adds two new directors to board

WALTHAM, Mass. - Surgical robotics company Vicarious Surgical Inc. (NYSE:RBOT), currently valued at $1.59 billion and showing strong momentum with a 27.61% gain last week, announced Monday the election of Fuad Ahmad and Joseph Doherty to i... Full story

Yahoo Finance • 7 months ago

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that V... Full story